TIGIT and COVID-19: To see whether similar effects can be observed in COVID-19, we assessed the frequencies of the co-inhibitory receptors PD1, TIGIT, BTLA, LAG-3, and TIM-3 on CD8+ and CD4+ T cells in COVID-19 and malaria patients and compared them with healthy individuals (Figure 3A).